analyses advancing today execute and has forward. of new from find made feedback the We're are an to on development Chris. rolling even important scientific positive received proud progress forward rewarding year our to and the moving we has congresses. NDA delivering franchises. pipeline at of from the for successfully team on we've scientific is And continuing look the submission key our What across more three community. readouts, where Thanks, multiple presenting And XXXX to I board data the tremendous zuranolone, morning across good marked everyone.
been As date. achieved note rewarding community on earlier, the and Chris progress you having that to of our and execution. to see It extremely continued heard all at is walk we've reflecting growth years of through of scientific part XX take Sage
new franchise. additional from franchises. our from data XXth included analyses site ECMP data European presented SHORELINE Study, recently XXXX and earlier Now, year. development The outcomes of program three health zuranolone depression the zuranolone. Congress. the provide shared SKYLARK our data economics support few data let and build on clinical the and Neuropsychopharmacology, Congress the the positive continue an themes with shared me at the We to of update and key on we've These analyses the well brain the presentations in Starting and or for from the potential to as of Study. a health I research, want data as that highlight the presentation College
particular, MDD onset showed analyses XX zuranolone of trials. highlight Study the day in First, with placebo, rapidity the compared patients In results our treatment PPD clinical as a seen and in of milligrams. the three from early both as effect zuranolone WATERFALL in
as through Study, or with day compared experienced the further depressive milligrams the get time across in-patients acting studies, study hoc the in in of MDD clinically SKYLARK early MDD with In reinforcing post zuranolone milligrams analysis sustained meaningful Further our patients patients meaningful. statistically clinically treated meaningful the both were XX. a Additionally, from XX to with improvements zuranolone improvements zuranolone to and belief XX early PPD of placebo, PPD. as in the results rapid, three that day rapid symptoms nature and clinically both were with periods, the significant
zuranolone. who trials Second, speak the on are in patients analyses durability effectiveness the clinical our seen to and in
Study to XX-day zuranolone patients who one were to Median the had with a to for XX% days MDD, the during the the received was in week who retreatment in be treatment that for demonstrated time opportunity Specifically, their responded two or milligram year. two the first responded XX initial up week study cohort. followed the with to two treatment those initial time treatment SHORELINE XXX among courses patients
seen with anxiety patients at in that the without and baseline. SKYLARK important including responses potential It's periods the across to across all highlights demonstrated both significant relates durability of durability. from trials for secondary measure, effect results with our clinical it to durability primary As patients Study across was time of which PPD data and statistically the zuranolone all positive MDD symptoms endpoints, broadly further note
elevated studies clear be symptoms a the to well Based As the date, the we broad of with studies for with in like depression and of STAR*D seen one MDD need are suited their patients know from range literature a with may zuranolone as poorest believe those the data to people on address anxiety of our we unmet MDD. outcomes. among
on or our as a of in of Third, the potential MDD. as the zuranolone add flexibility data clinical monotherapy therapy from suggests trials treatment
zuranolone a performs with existing current clinical analyses studies. events often the were discontinuation in to clinicians needs sexual approved. tolerated Additional seen of with Most treatment Zuranolone ADTs insight the PPD. clinical consistently analyses flexibility on adverse for well LANDSCAPE that in of with or lead add may gain across consistent have and meet on reinforced their whether program if these prior MDD as the MDD provide data studies the and common and dizziness, was with both sedation patients a SKYLARK generally somnolence, that as observed or as zuranolone of similarly further zuranolone novel the safety profile the use LANDSCAPE dysfunction headache, signals opportunity with and SHORELINE for monotherapy with development program well. programs These potential Overall, the shows an from data NEST weight treatment options. zuranolone no to seen and the therapy
function. executive Parkinson's label mild dementia or encouraging and or multiple have open and disease disease, PD, wholly our impairment turn as of Huntington's This being by like consistent in to demonstrated PAM. SAGE-XXX seen drivers investigating the SAGE-XXX, I'd a we people SAGE-XXX in certain developed for or Now the cognitive to disability. to Alzheimer's granted was of our main across receptor data impairment potential improvement We're impairment franchise Designation with one of Track is also of which NMDA FDA program HD. mild cognition a lead people and cognitive Fast Today, to led owned disorders that treatment studies cognitive is AD. cognitive is where due disease with mild and for due Neuropsychiatry by have impairment measures
Phase PARADIGM study the XX up progressing cognitive reported HD X additional extended ECMP PD. study supporting was Phase the of people through durable generally can SURVEYOR X executive in from consistent XX mild impairment are with function X controlled safety also with study placebo the response today days SAGE-XXX progressing due B treatment. the the SAGE-XXX with DIMENSION adverse with impairment. to of that showing follow in improvements We're We were cognitive observed well enrollment XX Part study and possibility PRECEDENT tolerated SAGE-XXX recently reported at and the Phase people and of the profile in and dosing, results events of sustained be in extended exposure enrollment Day of We with study today.
Day coding dementia mild endpoint AD. are follow-up controlled trial, designed patients or primary in both at Slide track study looking X four cognitive their due and more period. in measures on cognitive effects Adult we XX are older their change is on Phase in to week lives. on double-blind for adolescents. effects for study is Wechsler randomized also for patients XX-week performance apparent provide which with website. to a with one followed Additionally, study this cognitive and calling found be to the from trial, on of which excited impairment, that corporate to of the baseline this of that impairment, and the a performance Today, In changes intended can families to includes begin from provide performance widely study patients cognitive in the tolerability treatment around This be is XX mild safety, Intelligence placebo controlled that we're with evaluate The the adults in Phase can by the LIGHTWAVE This initiate deck is of to planned our will X the most placebo Edition. meaningful Scale-Fourth used XXXX. we're to the we study test period late AD SAGE-XXX cognitive design a The detail SAGE-XXX
additional In Daily assess the including addition, of and of we Questionnaire. effects plan on to and Activity Living Amsterdam performance measure endpoints [indiscernible] cognitive of the a variety to Instrumental SAGE-XXX functioning,
to updates ideas, help bring of important the the plan program help to get has been quest exchange key and we share congresses than never at Looking believe upcoming sooner. ahead, patients we better which scientific further more
dose neurological innovation treatment to regard of changing our a SAGE-XXX GABAA move or of holds that to has treatment fully to X We To this in like enrollment, our over options ranging ET completion was study ET on open by with sharing our led on updating number Phase guidance the have result by our SAGE-XXX, essential for particular had this conditions be years. SAGE-XXX a to I to a ET, no study dynamic Difficulty] generation the long-term The quarters. updates SAGE-XXX next that franchise of we tremor look coming in in in quarter's more I'll late neurology are enroll a the new limited a With in we allosteric [Technical modulator evaluating announced study moved of Now impact is Xb believe of now KINETIC that in on continue receptors. guidance XXXX. has team We expect initiated. label significant XX disease positive earnings study. that these We ET, close, X last the forward our that and Phase call amazed studies forward. pipeline potential factors
forward our sooner. our have efforts to help to health exciting medicines We remain and franchises. accelerating laser advancing look execution across to patients us on path I better develop get and of we three focused an ahead brain
call Kimi Now I'll over turn for Kimi? a of financials, our the review to
